REFERENCES
- Kokotas H, Petersen MB. Clinical and molecular aspects of aniridia. Clin Genet 2010 May;77:(5) 409–420.
- Lauderdale JD, Wilensky JS, Oliver ER, Walton DS, Glaser T. 3′ deletions cause aniridia by preventing PAX6 gene expression. Proc Natl Acad Sci USA 2000 Dec 5;97:(25) 13755–13759.
- Brauner SC, Walton DS, Chen TC. Aniridia. Int Ophthalmol Clin 2008 Spring;48:(2) 79–85.
- Cai F, Zhu J, Chen W, Ke T, Wang F, Tu X, Zhang Y, Jin R, Wu X. A novel PAX6 mutation in a large Chinese family with aniridia and congenital cataract. Mol Vis 2010 Jun 22;16:1141–1145.
- Davis LK, Meyer KJ, Rudd DS, Librant AL, Epping EA, Sheffield VC, Wassink TH. Pax6 3′ deletion results in aniridia, autism and mental retardation. Hum Genet 2008 May;123:(4) 371–378.
- D’Elia AV, Pellizzari L, Fabbro D, Pianta A, Divizia MT, Rinaldi R, Grammatico B, Grammatico P, Arduino C, Damante G. A deletion 3′ to the PAX6 gene in familial aniridia cases. Mol Vis 2007 Jul 23;13:1245–1250.
- Fantes J, Redeker B, Breen M, et al. Aniridia-associated cytogenetic rearrangements suggest that a position effect may cause the mutant phenotype. Hum Mol Genet 1995 Mar;4:(3) 415–422.
- Kleinjan DA, Seawright A, Schedl A, Quinlan RA, Danes S, van Heyningen V. Aniridia-associated translocations, DNase hypersensitivity, sequence comparison and transgenic analysis redefine the functional domain of PAX6. Hum Mol Genet 2001 Sep 15;10:(19) 2049–2059.
- Kleinjan DA, Seawright A, Mella S, Carr CB, Tyas DA, Simpson TI, Mason JO, Price DJ, van Heyningen V. Long-range downstream enhancers are essential for Pax6 expression. Dev Biol 2006 Nov 15;299:(2) 563–81.
- Redeker EJ, de Visser AS, Bergen AA, Mannens MM. Multiplex ligation-dependent probe amplification (MLPA) enhances the molecular diagnosis of aniridia and related disorders. Mol Vis 2008 May 7;14:836–840.